• Login
    View Item 
    •   UMB Digital Archive
    • UMB Open Access Articles
    • UMB Open Access Articles
    • View Item
    •   UMB Digital Archive
    • UMB Open Access Articles
    • UMB Open Access Articles
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of UMB Digital ArchiveCommunitiesPublication DateAuthorsTitlesSubjectsThis CollectionPublication DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    Statistics

    Display statistics

    Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Author
    Major, Ajay
    Kline, Justin
    Karrison, Theodore G
    Fishkin, Paul A S
    Kimball, Amy S
    Petrich, Adam M
    Nattam, Sreenivasa
    Rao, Krishna
    Sleckman, Bethany G
    Cohen, Kenneth
    van Besien, Koen
    Rapoport, Aaron P
    Smith, Sonali M
    Show allShow less

    Date
    2021-07-29
    Journal
    Haematologica
    Publisher
    Ferrata Storti Foundation
    Type
    Article
    
    Metadata
    Show full item record
    See at
    https://doi.org/10.3324/haematol.2021.278853
    Abstract
    The PI3K/Akt/mTOR (PAM) axis is constitutively activated in multiple lymphoma subtypes and is a promising therapeutic target. The mTOR inhibitor temsirolimus (TEM) and the immunomodulatory agent lenalidomide (LEN) have overlapping effects within the PAM axis with synergistic potential. This multicenter phase I/II study evaluated combination therapy with TEM/LEN in patients with relapsed and refractory lymphomas. Primary endpoints of the phase II study were rates of complete (CR) and overall response (ORR). There were 18 patients in the phase I dose-finding study, and TEM 25 mg weekly and LEN 20 mg on day 1 through day 21 every 28 days was established as the recommended phase II dose. An additional 93 patients were enrolled in the phase II component with three cohorts: diffuse large B-cell lymphoma (DLBCL, n=39), follicular lymphoma (FL, n=15), and an exploratory cohort of other lymphoma histologies with classical Hodgkin lymphoma (cHL) comprising the majority (n=39 total, n=20 with cHL). Patients were heavily pretreated with a median of 4 (range, 1-14) prior therapies and one-third with relapse following autologous stem cell transplantation (ASCT); patients with cHL had a median of 6 prior therapies. The FL cohort was closed prematurely due to slow accrual. ORR were 26% (13% CR) and 64% (18% CR) for the DLBCL and exploratory cohorts, respectively. ORR for cHL patients in the exploratory cohort, most of whom had relapsed after both brentuximab vedotin and ASCT, was 80% (35% CR). Eight cHL patients (40%) proceeded to allogeneic transplantation after TEM/LEN therapy. Grade ≥3 hematologic AEs were common. Three grade 5 AEs occurred. Combination therapy with TEM/LEN was feasible and demonstrated encouraging activity in heavily-pretreated lymphomas, particularly in relapsed/refractory cHL. ClinicalTrials.gov identifier: NCT01076543.
    Keyword
    temsirolimus
    Drug Therapy, Combination
    Ledalidomide
    Lymphoma--drug therapy
    Identifier to cite or link to this item
    http://hdl.handle.net/10713/16293
    ae974a485f413a2113503eed53cd6c53
    10.3324/haematol.2021.278853
    Scopus Count
    Collections
    UMB Open Access Articles

    entitlement

    Related articles

    • Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.
    • Authors: Diefenbach C, Kahl BS, McMillan A, Briones J, Banerjee L, Cordoba R, Miall F, Burke JM, Hirata J, Jiang Y, Paulson JN, Chang YM, Musick L, Abrisqueta P
    • Issue date: 2021 Dec
    • A Pilot Study of Lenalidomide Maintenance Therapy after Autologous Transplantation in Relapsed or Refractory Classical Hodgkin Lymphoma.
    • Authors: Shea L, Watkins MP, Wan F, Cashen AF, Wagner-Johnston ND, Jacoby MA, Abboud CN, Dipersio JF, Hurd DD, Jaglowski SM, Bartlett NL, Fehniger TA
    • Issue date: 2020 Dec
    • A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma - the STORM trial.
    • Authors: Witzens-Harig M, Memmer ML, Dreyling M, Hess G
    • Issue date: 2013 Jun 25
    • Brentuximab Vedotin and Bendamustine Produce Long-Term Clinical Benefit in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter Real-Life Experience.
    • Authors: Moretti M, Liberati AM, Rigacci L, Puccini B, Pulsoni A, Gini G, Galieni P, Fabbri A, Cantonetti M, Pavone V, Bolis S, Botto B, Renzi D, Falchi L
    • Issue date: 2022 Mar
    • Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.
    • Authors: Chen R, Palmer JM, Martin P, Tsai N, Kim Y, Chen BT, Popplewell L, Siddiqi T, Thomas SH, Mott M, Sahebi F, Armenian S, Leonard J, Nademanee A, Forman SJ
    • Issue date: 2015 Dec
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Policies | Contact Us | UMB Health Sciences & Human Services Library
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.